Queen May Innovation Ltd (QMI), is the wholly owned technology transfer subsidiary of Queen Mary, University of London. QMI is responsible for identifying, protecting and commercialising novel technologies in medicine and dentistry, healthcare, science and engineering. QMI manages a large and varied portfolio of licensed technologies and spin-out companies. With around 16,900 students, 3800 staff and an annual turnover of £300m, we are one of the biggest University of London colleges. The London School of Medicine and Dentistry faculty focuses on: translational research, cancer, cardiac, dentistry, inflammation, endocrinology/metabolism, immunology and infectious diseases, genomics, neuroscience, gastroenterology, epidemiology and primary care.
The Business Development Office provides access to Queen Mary University of London cutting-edge capabilities and state-of–the-art facilities. Our team of Business Development Managers will identify relevant academic expertise to meet your commercial requirements through collaborative research, contract research and consultancy.
Quotient Sciences are dedicated to accelerating the development of new drugs for patients around the world. They provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via their Translational Pharmaceutics® platform.. . For more than 30 years, Quotient Sciences has brought innovation to early drug development programs for pharmaceutical companies worldwide. At the company’s purpose built facilities, real-time manufacturing of all types of dosage forms is co-located with its clinical pharmacology unit to maximise flexibility, speed and cost savings for clients.
No data available
Established about 10 years ago to discover new anti-infection molecules to replace antibiotics and avoid resistance. We succeeded in creating a platform technology that offers several small molecules offering elimination of a range of pathogens to fight bacteria. viruses and fungal pathogens. It also offers performance in anti-aging, mental problems and solving many problems relating to the Gut Microbiome yet doing no damage to commensal bacteria or human cells. Our patent has been granted by EUIPO. Delivery systems have also been developed to work on other organs.
Reading Scientific Services Limited (RSSL) provides analytical, investigational, consultancy and training services to clients in the global biopharmaceutical, pharmaceutical and healthcare industries. We help our partners to develop drug products that are safe, innovative and of the highest quality.
Our GMP compliant facilities are located in the UK and with our team of more than 200 dedicated scientists, we ensure that every project is performed with our absolute commitment to outstanding quality, scientific excellence and customer satisfaction.
We offer a large portfolio of biological, microbiological, chemical and physical services to ensure the identity, purity, safety and quality of your biopharmaceutical through the full drug product life cycle.
Our comprehensive range of services include:
• Raw materials testing
• Biopharmaceutical characterisation
• Safety testing
• ICH stability testing
• Release testing
• Troubleshooting and contaminant identification
• 24/7 Emergency response service
• Training and consultancy
Our GMP compliant facilities are located in the UK and with our team of more than 200 dedicated scientists, we ensure that every project is performed with our absolute commitment to outstanding quality, scientific excellence and customer satisfaction.
We offer a large portfolio of biological, microbiological, chemical and physical services to ensure the identity, purity, safety and quality of your biopharmaceutical through the full drug product life cycle.
Our comprehensive range of services include:
• Raw materials testing
• Biopharmaceutical characterisation
• Safety testing
• ICH stability testing
• Release testing
• Troubleshooting and contaminant identification
• 24/7 Emergency response service
• Training and consultancy
With a client base representing companies from the FT Global 500 and FTSE listed companies, Reddie & Grose is recognised as a leading patent and trade mark firm. In 2009, the Managing Intellectual Property global patent survey ranked the firm as one of the UK’s top patent prosecution advisors. It consistently continues to achieve high rankings in all professional surveys.. . Reddie & Grose prides itself on delivering intellectual property protection for businesses in both the domestic and international marketplaces with a strong professional team of over 30 people from varied scientific backgrounds.. . The firm’s Cambridge office offers particular expertise in biotechnology, pharmaceutical, chemical, engineering, cleantech, instrumentation, medical device, materials, and software related inventions. Companies/academic institutions represented in this field by Reddie & Grose include: Diagnostics for the Real World, Haemostatix, Funxional Therapeutics, TCP Innovations, Trillion Genomics, Brax, Cambridge Biopolymers, Metalysis, University of Cambridge, Cambridge Broadband, i2, Cambridge Biotechnology Ltd and nCipher.. . Talk to us...
Watch our webinar with One Nucleus 'What are the IP Challenges at the Intersection of Life Sciences, Technology and Engineering Disciplines?' https://youtu.be/OHM3IoLoJ0Q
Watch our webinar with One Nucleus 'What are the IP Challenges at the Intersection of Life Sciences, Technology and Engineering Disciplines?' https://youtu.be/OHM3IoLoJ0Q
Horizon Discovery Group plc, a UK headquartered global life science company, is a world leader in gene editing and gene modulation. Through the application of these technologies the Company enables researchers to alter almost any gene or modulate its function in human or mammalian cells to generate models that mimic the genetic abnormalities found in diseases such as cancer. Horizon offers a catalogue of over 1,000,000 cell and reagent products, which along with related research services, support a greater understanding of the function of genes across all species and the genetic drivers of disease, and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, and are used in the Company’s own R&D pipeline.. . Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”. https://www.horizondiscovery.com . . •
No data available
Riverlabs is a new and exciting 28-acre life sciences campus, ideally situated at the centre of the ‘Golden Triangle’ in Ware, Hertfordshire. 440,000 sq ft (GIA) will be available in three phases:
• The most affordable, existing, purpose-built R&D space in the ‘Golden Triangle’. An intelligent refresh will transform existing labs into a modern, welcoming and sustainable working environment with staff wellbeing at its heart.
• Available for fit-out in January 2023, Riverlabs 1 provides 141,423 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Available for fit-out in May 2023, Riverlabs 2 provides 219,900 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Set within a unique, open campus environment enjoying natural waterfront to the River Lea. 15 acres of open green space plus sports club, tennis courts, cricket pitch, five-a-side football, access to water-based activities, river walks and nature on the doorstep.
• Perfectly positioned in an established life sciences ecosystem. Home to GSK for 50+ years, and within a 45-minute radius of major life science clusters in London, Cambridge and Stevenage, providing a huge pool of life sciences talent to recruit from.
To find out more visit https://www.riverlabsware.com
• The most affordable, existing, purpose-built R&D space in the ‘Golden Triangle’. An intelligent refresh will transform existing labs into a modern, welcoming and sustainable working environment with staff wellbeing at its heart.
• Available for fit-out in January 2023, Riverlabs 1 provides 141,423 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Available for fit-out in May 2023, Riverlabs 2 provides 219,900 sq ft (GIA) of ready-built, affordable, wet laboratory and write-up space.
• Set within a unique, open campus environment enjoying natural waterfront to the River Lea. 15 acres of open green space plus sports club, tennis courts, cricket pitch, five-a-side football, access to water-based activities, river walks and nature on the doorstep.
• Perfectly positioned in an established life sciences ecosystem. Home to GSK for 50+ years, and within a 45-minute radius of major life science clusters in London, Cambridge and Stevenage, providing a huge pool of life sciences talent to recruit from.
To find out more visit https://www.riverlabsware.com